Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
Nexalin Technology (Nasdaq: NXL) has received notice from Nasdaq confirming its regained compliance with the minimum bid price requirement under Rule 5550(a)(2). The notification was received on October 31, 2024. CEO Mark White emphasized this achievement as a significant milestone in the company's mission to develop non-invasive neurostimulation treatments, highlighting its importance for shareholder value and investor visibility as the company progresses with clinical research and global regulatory approvals.
Nexalin Technology (Nasdaq: NXL) ha ricevuto una comunicazione da Nasdaq che conferma la sua ristabilita conformità con il requisito del prezzo minimo per azione ai sensi della Regola 5550(a)(2). La notifica è stata ricevuta il 31 ottobre 2024. Il CEO Mark White ha sottolineato questo risultato come una pietra miliare significativa nella missione dell'azienda di sviluppare trattamenti di neurostimolazione non invasivi, evidenziando l'importanza per il valore per gli azionisti e la visibilità per gli investitori mentre l'azienda procede con la ricerca clinica e le approvazioni normative globali.
Nexalin Technology (Nasdaq: NXL) ha recibido una notificación de Nasdaq confirmando su reintegración a la normativa de cumplimiento del requisito de precio mínimo por acción bajo la Regla 5550(a)(2). La notificación fue recibida el 31 de octubre de 2024. El CEO Mark White enfatizó este logro como un hito significativo en la misión de la compañía de desarrollar tratamientos de neuroestimulación no invasivos, destacando su importancia para el valor de los accionistas y la visibilidad de los inversores a medida que la empresa avanza en la investigación clínica y las aprobaciones regulatorias globales.
Nexalin Technology (Nasdaq: NXL)는 Nasdaq으로부터 규정 5550(a)(2)에 따른 최소 매매가 요건을 재회복했다는 통지를 받았습니다. 이 통지는 2024년 10월 31일에 수신되었습니다. CEO 마크 화이트는 이 성과를 비침습적인 신경 자극 치료 개발에 대한 회사의 사명에서 중요한 이정표로 강조하며, 임상 연구와 글로벌 규제 승인을 진행함에 따라 주주 가치와 투자자 가시성의 중요성을 부각시켰습니다.
Nexalin Technology (Nasdaq: NXL) a reçu une notification de Nasdaq confirmant sa conformité rétablie avec l'exigence de prix minimum sous la règle 5550(a)(2). La notification a été reçue le 31 octobre 2024. Le PDG Mark White a souligné cette réalisation comme une étape significative dans la mission de l'entreprise de développer des traitements de neurostimulation non invasifs, mettant en avant son importance pour la valeur des actionnaires et la visibilité des investisseurs alors que l'entreprise progresse dans la recherche clinique et les approbations réglementaires mondiales.
Nexalin Technology (Nasdaq: NXL) hat von Nasdaq eine Benachrichtigung erhalten, die die Wiederherstellung der Konformität mit dem Mindestgebotsanforderung gemäß Regel 5550(a)(2) bestätigt. Die Benachrichtigung wurde am 31. Oktober 2024 erhalten. CEO Mark White betonte diesen Erfolg als einen bedeutenden Meilenstein in der Mission des Unternehmens, nicht-invasive Neurostimulationsbehandlungen zu entwickeln, und hob dessen Bedeutung für den Aktionärswert sowie die Sichtbarkeit der Investoren hervor, während das Unternehmen mit klinischen Forschungen und globalen Genehmigungen voranschreitet.
- Regained Nasdaq listing compliance, reducing delisting risk
- Maintained stock market visibility and accessibility to investors
- None.
Insights
Regaining Nasdaq compliance is a positive development that removes an immediate delisting risk and maintains the company's access to capital markets. However, this news has fundamental impact on Nexalin's business operations or financial outlook. With a micro-cap valuation of just
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).
"Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need," said Mark White, CEO of Nexalin. "This achievement not only underscores our commitment to driving shareholder value but also strengthens our visibility among investors as we make strides in clinical research and global regulatory approvals. We are deeply grateful to our shareholders for their steadfast support as we work to reshape the treatment landscape for mental health and neurological disorders."
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
RedChip Companies Inc.
Dave Gentry
407-644-4256
or 407-491-4498
nxl@redchip.com
FAQ
When did Nexalin Technology (NXL) regain Nasdaq compliance?
What Nasdaq requirement did Nexalin (NXL) comply with?
Why is Nasdaq compliance important for Nexalin (NXL)?
